SynthesisFrontiers in immunology2026
Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: a risk-stratified systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This systematic review and meta-analysis consolidates findings from recent randomized controlled trials (RCTs) on the efficacy of first-line immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI-TKI) combination therapy for metastatic renal cell carcinoma (mRCC). We also explored prognostic biomarkers and clinical factors to inform treatment strategies. Methods: We conducted a systematic search of PubMed, Embase, the Cochrane Library, Web of Science, and major conference proceedings for RCTs published from January 2016 to December 2025. The inclusion criteria were: (1) treatment-naïve patients with mRCC; (2) intervention with first-line ICI-TKI combination therapy; and (3) availability of extractable data for survival or safety endpoints. Effect estimates were aggregated using either a random-effects model (DerSimonian-Laird) or a fixed-effects model. Results: Six RCTs were included. The primary analysis of the overall population pooled data from five trials (N = 3,637), encompassing all risk groups defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Compared with control therapy, first-line ICI-TKI combination therapy significantly enhanced both progression-free survival (PFS), with a hazard ratio (HR) of 0.59 (95% confidence interval (CI) 0.51-0.67, P < 0.0001), and overall survival (OS), with an HR of 0.79 (95% CI 0.72-0.87, P < 0.0001). Efficacy varied by IMDC risk subgroup: favorable-risk patients exhibited a PFS benefit (HR 0.66, 95% CI 0.56-0.78, P < 0.0001) but no OS improvement (HR 0.96, 95% CI 0.79-1.18, P = 0.73); intermediate-risk patients had improved PFS (HR 0.60, 95% CI 0.53-0.69, P < 0.0001) and OS (HR 0.88, 95% CI 0.78-0.99, P = 0.03). Poor-risk patients derived the most substantial benefit, with improvements in both PFS (HR 0.50, 95% CI 0.41-0.61, P < 0.0001) and OS (HR 0.52, 95% CI 0.41-0.65, P < 0.0001). Conclusions: First-line combination therapy with ICI-TKI significantly improves both PFS and OS in patients with mRCC. The magnitude of clinical benefit is positively associated with higher IMDC risk scores, with the most substantial improvements in both PFS and OS observed in patients with poor-risk disease. Collectively, these findings establish ICI-TKI combination therapy as the standard first-line treatment for patients with intermediate or poor-risk mRCC. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251272113.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.